AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03102931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical to high (ROS/NOS) products
Description: Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
Study NCT00489554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses.
Study NCT02952339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 1030s vaccine
Description: 10\^5.0 PFU; administered as nose drops
Study NCT02952339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as nose drops
Study NCT00696852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
Study NCT00696852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
Study NCT00696852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, Relaxation, and Health Education
Description: The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
Study NCT02175420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Study NCT02175420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TFV
Study NCT02175420 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TFV
Study NCT02989350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM 17938 vs Placebo
Study NCT02989350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactobacillus reuteri DSM 17938 vs Placebo
Study NCT00489554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses.
Study NCT00925548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25) and Hormonal Treatment
Description: Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)
Study NCT00925548 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of tecemotide (L-BLP25) and Hormonal Treatment
Description: Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).
Study NCT00925548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
Study NCT00925548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride (NaCl)
Description: NaCl 9 g/L infusion
Study NCT03219411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamon
Description: Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
Study NCT03219411 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered orally as capsules three times a day over 12 weeks
Study NCT04214678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater clip closure
Description: Closure of post-resection defect with endoscopic clips by underwater technique
Study NCT04214678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional clip closure
Description: Closure of post-resection defect with endoscopic clip by conventional technique
Study NCT03788096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support with Motivational Interviewing
Description: Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
Study NCT04647929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
Study NCT02159911 — intervention group
Intervention type: DRUG
Intervention: Misoprostol administered orally one hour before surgery
Description: Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient.
Study NCT02759081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap-assisted water exchange
Description: a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
Study NCT02759081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water exchange
Description: water was infused and suctioned at the same time during insertion of colonoscope
Study NCT02759081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water exchange
Description: water was infused and suctioned at the same time during insertion of colonoscope
Study NCT01543776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: Given PO
Study NCT01543776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO
Study NCT03350906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n3-PUFA
Description: The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
Study NCT03350906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug but contains soybean oil with no active ingredient.
Study NCT03350906 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
Study NCT03350906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
Study NCT03350906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Body Composition Scan
Description: Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
Study NCT03350906 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body Composition Scan
Description: Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
Study NCT01877577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
Study NCT02995798 — intervention group
Intervention type: OTHER
Intervention: Cortical Bone thickness and Hounsfield unit (HU) numbers
Description: Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160mg
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 160mg placebo
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160mg placebo
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin 20mg placebo
Study NCT01918332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg placebo
Study NCT00511316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast/ Singulair
Description: 20 mg daily for six months
Study NCT00511316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg daily for 6 months
Study NCT00731692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
Study NCT03150628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Description: Perioperative chemotherapy
Study NCT03150628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Cytoreductive surgery
Study NCT03150628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
Study NCT01324869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KH902
Description: Intravitreal injection of 0.5mg/eye/time KH902
Study NCT01575314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stapling device
Description: Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
Study NCT04267081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Ex vivo venetoclax sensitivity testing is used for patient selection.
Study NCT05702086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)
Description: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
Study NCT05702086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)
Description: SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
Study NCT02795325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PH1
Description: IV infusion of DCR-PH1
Study NCT02795325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00789672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
Study NCT00731692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules were administered orally once daily
Study NCT02297464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs - 2 per day for breakfast
Description: 11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
Study NCT03431467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella-CP LV Vent
Description: Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
Study NCT02172326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation capsules for oral inhalation
Description: Powder inhalation via HandiHaler®
Study NCT04793893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReLex Smile
Description: With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
Study NCT01522599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARDS-Net Strategy
Description: Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
Study NCT01522599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECCO2-R
Description: Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
Study NCT01496781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemoclip
Description: Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
Study NCT01496781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EndoClot
Description: EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
Study NCT02216227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
Study NCT02216227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery.
Study NCT03788096 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Group
Description: Usual care.
Study NCT01323361 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Laparoscopic ventral hernia repair
Description: Patients operated with laparoscopic repair of ventral or incisional hernia
Study NCT02743429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinutuximab beta
Description: Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days.
Study NCT04133987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine admixture TV005
Description: The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
Study NCT02939560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar® TMS device (Neuronetics, Atlanta, GA)
Description: Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
Study NCT02216227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: All patients will receive Cefazolin during surgery
Study NCT04606576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fish Oil
Study NCT04606576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 QD
Description: Oral Insulin once per day
Study NCT04606576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 BD
Description: Oral Insulin, twice per day
Study NCT01191580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
Study NCT01191580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
Study NCT01191580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy
Description: The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures.
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol 2000 IU orally, daily
Description: ergocalciferol 2000 IU orally, daily
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol 25000 IU oraly every 2 weeks
Description: ergocalciferol 25000 IU oraly every 2 weeks
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol 50000 IU orally every 4 weeks
Description: ergocalciferol 50000 IU orally every 4 weeks
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocal1000 IU & cholecal 1000 IU orally daily
Description: ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol 2000 IU orally daily
Description: cholecalciferol 2000 IU orally everyday
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 25000 IU orally every 2 weeks
Description: Cholecalciferol 25000 IU orally every 2 weeks
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 50000 orally every 4 weeks
Description: Cholecalciferol 50000 orally every 4 weeks
Study NCT01170494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo orally everyday
Description: placebo orally everyday
Study NCT01569958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
Study NCT02216227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.